PTAB Says Rituxan Patent Challenged By Pfizer Is Obvious

Law360 (November 1, 2018, 7:03 PM EDT) -- The Patent Trial and Appeal Board on Wednesday handed a win to Pfizer Inc. in its challenge of a Biogen Inc. patent covering the cancer treatment Rituxan, with the board invalidating the patent as obvious because of previous drug trials.

In a 39-page decision, the PTAB found that Biogen’s patent was invalid as obvious in light of a combination of earlier drug trials and studies relating to various high-dose therapy on patients with blood cancer, including non-Hodgkin’s lymphoma.

The board found that it would have been obvious for a person ordinarily skilled in the art to combine a trial known as...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!